FDA Approval for new AML drug/ Richard Stone, MD, Dana-Farber
868 views · Published 28 April 2017 · 1:37 · Indexed 14 October 2026
Channel: Dana-Farber Cancer Institute · 2017 · Science & Technology
Dr. Richard Stone, Chief of Staff, Adult Leukemia Program Director at Dana-Farber Cancer Institute, led research leading to the Food and Drug Administration approving Midostaurin for treating patients with Acute myeloid leukemia or AML.
More from this channel
-
0:18
Importance of Joining the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:20
How to Join the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:18
How to Register as a Stem Cell Donor | Dana-Farber Cancer Institute
-
3:03
Sportscaster Jim Britt for the Jimmy Fund | Dana-Farber Cancer Institute
-
0:07
Dana-Farber Banners | Dana-Farber Cancer Institute
-
2:08
Barbers for the Jimmy Fund | Dana-Farber Cancer Institute
-
1:43
Pets | Dana-Farber Cancer Institute
-
1:34
Healthy Eating for the Holiday Season | Dana-Farber Cancer Institute